Potential therapeutic agents against COVID-19: What we know so far. Issue 6 (1st April 2020)

• Record Type: Journal Article
• Authors: Lu, Chih-Chia; Chen, Mei-Yu; Lee, Wan-Shin; Chang, Yuh-Lih
• Is Part Of: Journal of the Chinese Medical Association. Volume 83:Issue 6(2020)
• Page Start: 534
• Page End: 536
• Publication Date: 2020-04-01
• Subjects: Chloroquine -- COVID-19 -- Favipiravir -- Hydroxychloroquine -- Interferon -- Lopinavir/ritonavir -- Remdesivir -- Ribavirin -- Sarilumab -- Severe acute respiratory syndrome coronavirus 2 -- Tocilizumab; Medicine -- Periodicals; 610.5
• DOI: 10.1097/JCMA.0000000000000318
• Languages: English
• ISSNs: 1726-4901

Abstract

Abstract : The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab, and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.